| Product No | EMEA/H/C/003756 |
|---|---|
| Brand Name | Jylamvo |
| Nonproprietary Name | methotrexate |
| API | Methotrexate |
| ATC Code | L04AX03 |
| Indications | In rheumatological and dermatological diseasesActive rheumatoid arthritis in adult patients.Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response to non-steroidal anti-inflammatory drugs (NSAIDs) has been inadequate.Severe, treatment-refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy and retinoids, and severe psoriatic arthritis in adult patients.In oncologyMaintenance treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children aged 3 years and over. |
| Orphan Drug | no |
| Generics | no |
| Marketing Authorization Holder | Therakind (Europe) Limited |
| Status | Authorised(授权) |
| Authorization Date | 2017-03-29 |
| Version | 12 |
| Condition Approval | no |
| Exceptions | no |
| Biosimilar | no |
| Details | 查看 (公众评估报告、授权细节、产品规格/剂型、标签、历史评估信息) |
Extended Information